, Volume 260, Issue 7, pp 561-562,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 14 Feb 2010

Is the word ‘biomarker’ being properly used by proteomics research in neuroscience?

This is an excerpt from the content

Lately, when researchers see an article with the word “biomarker”, they feel, at least, suspicious. Sometimes, even scared and such feeling of distrust occurs mostly because the majority of the published articles in the field of global proteome analysis are revealing, for instance, differentially expressed proteins in pathologic conditions and claiming that biomarkers are being discovered. In addition to transform a differentially expressed protein in a biomarker, a long road has to be travelled.

Biomarker is defined by the United States Food and Drug Administration (FDA) as “a characteristic that is objectively measured and evaluated as an indicator of normal biologic or pathogenic processes or pharmacological responses to a therapeutic intervention” [1]. Such definition is, indeed, quite specific and very different from a differentially expressed protein discovered as potentially related to some disease in a small set of sample. Therefore, researchers are totally correct regarding the ...